Correction: Management of hepatitis B

An error occurred in Table 2 of the article Elgouhari HM, Abu-Rajab Tamimi, Carey W. Hepatitis B: A strategy for evaluation and management. Cleve Clin J Med 2009; 76:19–35. In the lamivudine column, the information on drug resistance, pregnancy risk category, and cost was incorrect. The corrected table is reproduced below and online. Also, the bulleted text in the first column of page 24 should read: “Chronic inactive carriers who have no e antigen, persistently normal ALT levels, and very low or undetectable levels of HBV DNA without evidence of significant liver injury.”

 

An error occurred in Table 2 of the article Elgouhari HM, Abu-Rajab Tamimi, Carey W. Hepatitis B: A strategy for evaluation and management. Cleve Clin J Med 2009; 76:19–35. In the lamivudine column, the information on drug resistance, pregnancy risk category, and cost was incorrect. The corrected table is reproduced below and online. Also, the bulleted text in the first column of page 24 should read: “Chronic inactive carriers who have no e antigen, persistently normal ALT levels, and very low or undetectable levels of HBV DNA without evidence of significant liver injury.”

 

An error occurred in Table 2 of the article Elgouhari HM, Abu-Rajab Tamimi, Carey W. Hepatitis B: A strategy for evaluation and management. Cleve Clin J Med 2009; 76:19–35. In the lamivudine column, the information on drug resistance, pregnancy risk category, and cost was incorrect. The corrected table is reproduced below and online. Also, the bulleted text in the first column of page 24 should read: “Chronic inactive carriers who have no e antigen, persistently normal ALT levels, and very low or undetectable levels of HBV DNA without evidence of significant liver injury.”